Scottish biotech ILC Therapeutics has set its sights on a Series A round and an IPO following its most recent investment round and is on track to commercialise a suite of antiviral medicines for the treatment of respiratory infections including

Scottish biotech ILC Therapeutics has signed a R&D partnership with international veterinary group Dechra Pharmaceuticals PLC  which will see both entities develop ILC’s Caniferon product to treat atopic dermatitis in dogs. Atopic dermatitis is the most common form of eczema affecting

• Drug also has potential to treat SARS, HIV, hepatitis and respiratory infection (RSV)• Earlier research shows drug is 15-20 times more potent than other interferons• Far fewer side effects than current treatments ILC Therapeutics has completed in vivo tests